Spots Global Cancer Trial Database for recurrent grade 3 follicular lymphoma

Every month we try and update this database with for recurrent grade 3 follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00019708	Extranodal Marg... Nodal Marginal ... Non-Hodgkin Lym... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu...	tanespimycin	19 Years -	National Cancer Institute (NCI)
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation	NCT00003056	Leukemia Lymphoma Graft Versus Ho...	cyclosporine cyclosporine an...	18 Years - 55 Years	Takeda
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer	NCT00546377	Leukemia Lymphoma	filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease	NCT00176475	Leukemia Lymphoma Multiple Myelom...	rituximab therapeutic all...	18 Years -	Rutgers, The State University of New Jersey
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation	NCT00003143	Lymphoma	Amifostine DHAP	18 Years -	Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma	NCT00538187	Adult Non-Hodgk... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small...	obatoclax mesyl... bortezomib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00119392	B-cell Chronic ... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac...	rituximab cyclosporine fludarabine pho... mycophenolate m... yttrium Y 90 ib... peripheral bloo... allogeneic hema... total-body irra...	18 Years -	Fred Hutchinson Cancer Center
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma	NCT00863369	Lymphoma	rituximab bortezomib gemcitabine hyd... questionnaire a...	18 Years -	City of Hope Medical Center
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma	NCT00020462	Lymphoma	aldesleukin autologous tumo...	18 Years -	National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma	NCT00003039	Lymphoma	alvocidib	18 Years -	National Cancer Institute (NCI)
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma	NCT00002649	Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade...	aldesleukin filgrastim cyclophosphamid... etoposide radiation thera... peripheral bloo... bone marrow abl...	16 Years - 60 Years	National Cancer Institute (NCI)
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma	NCT00052442	Lymphoma	pralatrexate	18 Years -	Spectrum Pharmaceuticals, Inc
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	NCT00980395	Lymphoma Mantle Cell Lym... Indolent Lympho... SLL	rituximab bortezomib cladribine	18 Years -	University of Arizona
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT00265928	Lymphoma	bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti...	18 Years -	National Cancer Institute (NCI)
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma	NCT00334438	Lymphoma	rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri...	18 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202	NCT00896662	Lymphoma Solid Tumor	immunologic tec... laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	NCT00005601	Lymphoma	rituximab cisplatin cytarabine dexamethasone sargramostim	18 Years -	Alliance for Clinical Trials in Oncology
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00007852	Lymphoma	rituximab carmustine cytarabine etoposide melphalan autologous hema...	19 Years -	University of Nebraska
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma	NCT00004192	Lymphoma Neutropenia	filgrastim pegfilgrastim cisplatin cytarabine etoposide methylprednisol...	18 Years - 120 Years	University of Nebraska
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma	NCT00007865	Lymphoma	rituximab carboplatin etoposide ifosfamide	19 Years - 120 Years	University of Nebraska
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma	NCT00003039	Lymphoma	alvocidib	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma	NCT00002697	Lymphoma	filgrastim sargramostim carboplatin etoposide ifosfamide autologous bone... bone marrow abl... peripheral bloo... radiation thera...	18 Years - 65 Years	Memorial Sloan Kettering Cancer Center
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00244985	Lymphoma	rituximab pegylated lipos...	18 Years - 120 Years	Roswell Park Cancer Institute
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma	NCT00334438	Lymphoma	rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri...	18 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	NCT00003661	Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma	anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	- 54 Years	Roswell Park Cancer Institute
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01812005	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	alisertib rituximab laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation	NCT00003143	Lymphoma	Amifostine DHAP	18 Years -	Jonsson Comprehensive Cancer Center
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00082823	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma	NCT00310167	Lymphoma	radiation thera...	18 Years -	University College, London
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	NCT04205409	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Recurrent Plasm... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Plas... Recurrent Mantl... Refractory Mant...	Nivolumab	18 Years -	University of Washington
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00002908	Leukemia Lymphoma	bryostatin 1 vincristine sul...	18 Years -	Barbara Ann Karmanos Cancer Institute
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma	NCT00848328	Lymphoma	Rituximab Lenalidomide	18 Years -	University of California, Davis
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	NCT00005589	Lymphoma	filgrastim rituximab carmustine cyclophosphamid... cytarabine etoposide melphalan bone marrow abl... peripheral bloo...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	NCT00004179	Lymphoma	rituximab CHOP regimen cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	18 Years - 120 Years	European Organisation for Research and Treatment of Cancer - EORTC
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003397	Lymphoma	filgrastim rituximab sargramostim carmustine cisplatin cyclophosphamid... dexamethasone etoposide gemcitabine hyd... melphalan paclitaxel bone marrow abl... peripheral bloo...	18 Years - 75 Years	University of Maryland, Baltimore
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer	NCT00248430	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom...	aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo...	18 Years - 69 Years	Fred Hutchinson Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma	NCT00002471	Leukemia Lymphoma	asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... methotrexate methylprednisol... therapeutic hyd... thiotepa vincristine sul...	-	Memorial Sloan Kettering Cancer Center
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00040950	Lymphoma	rituximab agatolimod sodi...	18 Years -	National Cancer Institute (NCI)
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00062296	Leukemia Lymphoma	rituximab epirubicin hydr...	18 Years -	Fox Chase Cancer Center
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma	NCT00691652	Lymphoma	rituximab clofarabine DNA methylation... gene expression... microarray anal... polymerase chai... high performanc... laboratory biom...	18 Years - 89 Years	OHSU Knight Cancer Institute
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT01045928	Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac...	lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom...	18 Years -	Case Comprehensive Cancer Center
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL	NCT00732498	Lymphoma	Methylprednisol... Etoposide Cytarabine Cisplatin Rituximab In-Zevalin Y-Zevalin	18 Years -	University of Arizona
Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma	NCT00002510	Lymphoma	filgrastim cyclophosphamid... etoposide mesna peripheral bloo... radiation thera...	16 Years - 65 Years	Temple University
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer	NCT02240719	Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Refractory Chro... Multiple Myelom...	everolimus bendamustine hy...	18 Years -	University of California, Davis
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00110071	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	fludarabine pho... peripheral bloo... iodine I 131 to... laboratory biom... flow cytometry polymerase chai...	60 Years -	Fred Hutchinson Cancer Center
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	NCT00010192	B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ...	rituximab aldesleukin laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	NCT02281279	B-cell Adult Ac... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	rituximab lenalidomide romidepsin laboratory biom...	18 Years -	Mayo Clinic
PS-341 in Treating Patients With Advanced Cancer	NCT00006362	Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu...	bortezomib	18 Years -	Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00005592	Lymphoma	90-Y-ibritumoma... rituximab indium In 111 i...	18 Years -	University of Alabama at Birmingham
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	NCT00002880	Lymphoma	Etoposide phosp...	-	Alliance for Clinical Trials in Oncology
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma	NCT02049541	Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu...	18 Years -	Ohio State University Comprehensive Cancer Center
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00040950	Lymphoma	rituximab agatolimod sodi...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer	NCT00782379	Leukemia Lymphoma Myelodysplastic...	busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo...	18 Years - 60 Years	Northside Hospital, Inc.
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma	NCT01849263	Grade 3a Follic... Recurrent Grade... Recurrent Grade... Recurrent Grade... Refractory Foll...	Ibrutinib Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	NCT00003661	Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma	anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	- 54 Years	Roswell Park Cancer Institute
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00110071	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	fludarabine pho... peripheral bloo... iodine I 131 to... laboratory biom... flow cytometry polymerase chai...	60 Years -	Fred Hutchinson Cancer Center
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00073918	Anaplastic Larg... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	cyclophosphamid... etoposide iodine I 131 to... quality-of-life... peripheral bloo...	18 Years - 60 Years	Fred Hutchinson Cancer Center
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	NCT00980395	Lymphoma Mantle Cell Lym... Indolent Lympho... SLL	rituximab bortezomib cladribine	18 Years -	University of Arizona
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma	NCT00334438	Lymphoma	rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri...	18 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma	NCT00006669	Lymphoma	rituximab sargramostim EPOCH regimen cyclophosphamid... doxorubicin hyd... etoposide prednisone vincristine sul...	18 Years - 120 Years	Medstar Health Research Institute
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms	NCT00082784	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Refractory Plas... Splenic Margina... Waldenstrom Mac...	Bortezomib Alvocidib Hydro... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma	NCT00089115	Lymphoma	autologous immu... rituximab sargramostim	18 Years -	National Cancer Institute (NCI)
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma	NCT00004192	Lymphoma Neutropenia	filgrastim pegfilgrastim cisplatin cytarabine etoposide methylprednisol...	18 Years - 120 Years	University of Nebraska
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia	NCT00004107	Leukemia Lymphoma	filgrastim autologous bone... peripheral bloo... indium In 111 m... yttrium Y 90 ep...	18 Years - 80 Years	Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	NCT00275080	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Secondary Acute... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Untreated Adult... Untreated Adult...	vorinostat decitabine	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00012298	Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac...	rituximab yttrium Y 90 ib... indium In 111 i... oprelvekin filgrastim	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: